At least 10 compounds are in clinical development for Duchenne muscular dystrophy (DMD). The therapies include compounds that target the dysfunctional or absent dystrophin gene, as well as compounds that hit pathways downstream of the dystrophin gene to reduce muscle-associated inflammation, fibrosis and wasting. (A) GlaxoSmithKline plc (LSE:GSK; NYSE:GSK